Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...

Scientists are finding that coffee pods and cups may contribute to this problem. Many coffee pods and single-serve cups ...

The Food and Drug Administration awarded the drug’s sponsor, biotech company Revolution Medicines, a new and unconventional ...

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agreed-on deal ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments—such as monoclonal antibodies—sooner.

Developers of biosimilars will no longer be required to conduct clinical trials to prove effectiveness for FDA approval.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial ...

This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s ...